Changing 340B is the wrong prescription for addressing skyrocketing pharmaceutical costs

Blog

The rapidly rising costs of prescription drugs is causing significant financial challenges for patients and their care providers.

Many groups, including the AHA, are evaluating options for addressing this important issue. However, one recent proposal, which is seriously misguided, would reduce a program... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Complex Care Found at Facilities Affiliated with Hospitals and Health Systems

Blog

A recent study that claims cancer care is more expensive because hospitals are employing more physicians is misleading and does not consider all of the facts. 

The study had several problematic areas. While it accounts for changes in the general rate of inflation, there is no indication that the authors... read more

Topic: Access and Coverage
Tags: mergers, site neutral payment, price, care coordination

Stop Unsustainable Drug Prices

Blog

Today’s New York Times provides arguments from drug companies justifying the excessive jump in pharmaceutical prices in recent years, saying the higher prices won’t impact patients. 

Hospitals’ top priority is providing patients with safe and effective care, but the skyrocketing costs of pharmaceuticals... read more

Topic: Access and Coverage
Tags: access, price, drug prices

Flawed Paper Attempts to Link Hospital Concentration and Price

Blog

A report released last month used commercial claims data from United Healthcare (United), Aetna and Humana to reach a number conclusions about hospital prices and concentration. The paper is badly flawed and the assertions made about hospital market structure and prices, in particular, should be viewed as... read more

Topic: Advocacy and Public Policy
Tag: price

Study finds no systematic quantifiable relationship between price and concentration

Blog

A new study out today conflicts head on with an April 2015 study by a leading health care expert and antitrust economist that found “concentration or structure alone is not a meaningful or reliable predictor of price changes.”  Both studies relied on commercial data, but the latter had authors who were... read more

Topic: Access and Coverage
Tag: price

Protect Patients. Preserve 340B.

Blog

More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and decreasing... read more

Topic: Access and Coverage
Tags: 340B, Drug Pricing Program, access, price, drug prices

Mega Insurance Deals Not Good for Consumers

Blog

The recently announced mega deals in the insurance industry will lead to further consolidation of an already highly concentrated health insurance market and will not benefit consumers says an opinion piece in Law360. The column, authored by former policy director of the Bureau of Competition at the... read more

Topics: Access and Coverage, Community Health
Tags: acquisitions, mergers, Coverage, access, price, clinical integration, care coordination, antitrust

Who benefits from insurance mega-deals?

Blog

Recent announcements about commercial insurance company acquisitions continue to send up red flags and with good reason. The question on everyone’s mind is: How can these mega-deals possibly benefit consumers? The insurance industry already is enormously concentrated and has a dismal track record of... read more

Topic: Access and Coverage
Tags: acquisitions, consolidation, mergers, Coverage, access, price, antitrust

Further Confirmation of Transformation

Blog

The Journal of the American Medical Association uses the term “jaw-dropping” to describe the conclusions of a new study that finds deaths, hospitalizations and costs all going down for patients in Medicare’s traditional “fee-for-service” program. (Data were not available for managed care patients.) We see... read more

Topics: Quality and Patient Safety, Community Health
Tags: quality care, quality, safety, price

A Little Good, a Little Bad

Blog

The news often brings some good and some bad; sometimes a step forward and a step back. This week’s good news is the proposed change that would allow payment for advanced care planning visits with clinicians, encouraging dialogs that will help patients determine how they want care provided in serious... read more

Topics: Access and Coverage, Advocacy and Public Policy
Tags: physician issues, physicians, Drug Pricing Program, advocacy, financial assistance, price

Keyword Search

Date